GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Five Prime Therapeutics Inc (NAS:FPRX) » Definitions » Operating Margin %

Five Prime Therapeutics (Five Prime Therapeutics) Operating Margin % : 3,104.94% (As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Five Prime Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Five Prime Therapeutics's Operating Income for the three months ended in Dec. 2020 was $-21.98 Mil. Five Prime Therapeutics's Revenue for the three months ended in Dec. 2020 was $-0.71 Mil. Therefore, Five Prime Therapeutics's Operating Margin % for the quarter that ended in Dec. 2020 was 3,104.94%.

The historical rank and industry rank for Five Prime Therapeutics's Operating Margin % or its related term are showing as below:

FPRX' s Operating Margin % Range Over the Past 10 Years
Min: -954.27   Med: -285.8   Max: 75.56
Current: -677.93


FPRX's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -172 vs FPRX: -677.93

Five Prime Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Five Prime Therapeutics's Operating Income for the three months ended in Dec. 2020 was $-21.98 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2020 was $-92.87 Mil.


Five Prime Therapeutics Operating Margin % Historical Data

The historical data trend for Five Prime Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Five Prime Therapeutics Operating Margin % Chart

Five Prime Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -323.26 -383.22 -293.08 -954.27 -704.74

Five Prime Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -999.97 -245.22 -500.70 -1,616.70 3,104.94

Competitive Comparison of Five Prime Therapeutics's Operating Margin %

For the Biotechnology subindustry, Five Prime Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Five Prime Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's Operating Margin % falls into.



Five Prime Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Five Prime Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-92.87 / 13.178
=-704.74 %

Five Prime Therapeutics's Operating Margin % for the quarter that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=-21.983 / -0.708
=3,104.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Five Prime Therapeutics  (NAS:FPRX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Five Prime Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Five Prime Therapeutics (Five Prime Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.
Executives
William R Ringo director
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
David White officer: See Remarks 4560 HORTON STREET EMERYVILLE CA 94608
Helen Louise Collins officer: EVP and Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451

Five Prime Therapeutics (Five Prime Therapeutics) Headlines

From GuruFocus

Five Prime Announces Closing of Upsized Public Offering of Common Stock

By Business Wire Business Wire 11-18-2020

Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157

By Business Wire Business Wire 11-12-2020